Ann Rheum Dis:药物诱发的系统性狼疮

2019-02-19 xiangting MedSci原创

这项研究确定了118种与DIL相关的药物。在面对潜在的DIL病例时,这个疑似药物清单对医生有所帮助。

药物性狼疮(DIL)是一种特殊的治疗副作用,其症状与系统性红斑狼疮(SLE)存在重叠。DIL疾病谱随着药典的发展而不断变化。这项研究使用世界卫生组织WHO全球个案病例安全报告(ICSRs)数据库-VigiBase来确定与DIL相关的主要药物。

研究人员根据药物监管医学词典(优选术语水平)分析了VigiBase中所有被归类为"系统性红斑狼疮"的ICSRs。分析中考虑的药物是那些不用于治疗SLE,并且不成比例贝叶斯报告的指标值,即信息因子(IC025)95%可信区间的正下限≥0的药物。

使用VigiBase共确定了12166例DIL ICSRs。其中,提取了关于118种IC025≥0疑似药物的8163例ICSRs。DIL发病的中位年龄为49岁,女:男的性别比为4.3。开始疑似治疗与出现DIL间的延迟中位数为172天。55.4%的ICSRs中DIL被报告为严重不良事件。118种疑似药物中,42种药物既往未被报告与DIL有关。与最多的DIL病例数量相关的药物是英夫利昔单抗、阿达木单抗、依那西普、普鲁卡因胺和肼苯哒嗪。

这项研究确定了118种与DIL相关的药物。在面对潜在的DIL病例时,这个疑似药物清单对医生有帮助。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012954, encodeId=d62c2012954b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 28 03:43:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017120, encodeId=7cdc201e12094, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Jun 11 08:43:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387323, encodeId=a41c138e323c2, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Feb 21 00:43:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
    2019-05-28 仁医06
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012954, encodeId=d62c2012954b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 28 03:43:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017120, encodeId=7cdc201e12094, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Jun 11 08:43:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387323, encodeId=a41c138e323c2, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Feb 21 00:43:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012954, encodeId=d62c2012954b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 28 03:43:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2017120, encodeId=7cdc201e12094, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Tue Jun 11 08:43:00 CST 2019, time=2019-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387323, encodeId=a41c138e323c2, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Thu Feb 21 00:43:00 CST 2019, time=2019-02-21, status=1, ipAttribution=)]